Integrated Network Pharmacology Analysis and Experimental Validation to Investigate the Molecular Mechanism of Triptolide in the Treatment of Membranous Nephropathy

References

• Ronco P, Debiec H. Molecular pathogenesis of membranous nephropathy. Annu Rev Pathol. 2020;15(1):287–313. doi:10.1146/annurev-pathol-020117-043811
   PubMed Web of Science ®Google Scholar
• Beck LH, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21. doi:10.1056/NEJMoa0810457
   PubMed Web of Science ®Google Scholar
• Tomas NM, Beck LH, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–2287. doi:10.1056/NEJMoa1409354
   PubMed Web of Science ®Google Scholar
• Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983–997. doi:10.2215/CJN.11761116
   PubMed Web of Science ®Google Scholar
• Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69. doi:10.1038/s41572-021-00303-z
   PubMed Web of Science ®Google Scholar
• Xu X, Wang G, Chen N, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016;27(12):3739–3746. doi:10.1681/ASN.2016010093
   PubMed Web of Science ®Google Scholar
• Alsharhan L, Beck LH. Membranous nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;77(3):440–453. doi:10.1053/j.ajkd.2020.10.009
   PubMed Web of Science ®Google Scholar
• Wang YN, Feng HY, Nie X, et al. Recent advances in clinical diagnosis and pharmacotherapy options of membranous nephropathy. Front Pharmacol. 2022;13:907108. doi:10.3389/fphar.2022.907108
   PubMed Web of Science ®Google Scholar
• Chen Y, Deng Y, Ni Z, et al. Efficacy and safety of traditional Chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial. Am J Kidney Dis. 2013;62(6):1068–1076. doi:10.1053/j.ajkd.2013.05.005
   PubMed Web of Science ®Google Scholar
• Lu H, Luo Y, Su B, et al. Wenyang Lishui decoction ameliorates podocyte injury in membranous nephropathy rat and cell models by regulating p53 and Bcl-2. Evid Based Complement Alternat Med. 2020;2020:6813760. doi:10.1155/2020/6813760
   PubMed Web of Science ®Google Scholar
• Tian R, Wang L, Chen A, et al. Sanqi oral solution ameliorates renal damage and restores podocyte injury in experimental membranous nephropathy via suppression of NFkappaB. Biomed Pharmacother. 2019;115:108904. doi:10.1016/j.biopha.2019.108904
   PubMed Web of Science ®Google Scholar
• Law SK, Simmons MP, Techen N, et al. Molecular analyses of the Chinese herb Leigongteng (Tripterygium wilfordii Hook.f.). Phytochemistry. 2011;72(1):21–26. doi:10.1016/j.phytochem.2010.10.015
   PubMed Web of Science ®Google Scholar
• Kupchan SM, Court WA, Dailey RG, Gilmore CJ, Bryan RF. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc. 1972;94(20):7194–7195. doi:10.1021/ja00775a078
   PubMed Web of Science ®Google Scholar
• Gao J, Zhang Y, Liu X, Wu X, Huang L, Gao W. Triptolide: pharmacological spectrum, biosynthesis, chemical synthesis and derivatives. Theranostics. 2021;11(15):7199–7221. doi:10.7150/thno.57745
   PubMed Web of Science ®Google Scholar
• Bai S, Hu Z, Yang Y, et al. Anti-inflammatory and neuroprotective effects of triptolide via the NF-kappaB signaling pathway in a Rat MCAO model. Anat Rec. 2016;299(2):256–266. doi:10.1002/ar.23293
   Google Scholar
• Hou W, Liu B, Triptolide: XH. Medicinal chemistry, chemical biology and clinical progress. Eur J Med Chem. 2019;176:378–392. doi:10.1016/j.ejmech.2019.05.032
   PubMed Web of Science ®Google Scholar
• Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS, Liu ZH. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int. 2008;74(5):596–612. doi:10.1038/ki.2008.203
   PubMed Web of Science ®Google Scholar
• Chen ZH, Qin WS, Zeng CH, et al. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int. 2010;77(11):974–988. doi:10.1038/ki.2010.41
   PubMed Web of Science ®Google Scholar
• Guo Y, Guo N, Wang J, Wang R, Tang L. Retrospective analysis of Tripterygium wilfordii polyglycoside combined with angiotensin receptor blockers for the treatment of primary membranous nephropathy with sub-nephrotic proteinuria. Ren Fail. 2021;43(1):729–736. doi:10.1080/0886022X.2021.1918555
   PubMed Web of Science ®Google Scholar
• Zheng Q, Yang H, Liu W, et al. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis. BMJ Open. 2019;9(9):e030919. doi:10.1136/bmjopen-2019-030919
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11. doi:10.1186/1752-0509-8-S4-S11
   PubMed Web of Science ®Google Scholar
• Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient’s care. Lancet. 2015;385(9981):1983–1992. doi:10.1016/s0140-6736(15)60731-0
   PubMed Web of Science ®Google Scholar
• Beck LH, Salant DJ. Membranous nephropathy: from models to man. J Clin Invest. 2014;124(6):2307–2314. doi:10.1172/JCI72270
   PubMed Web of Science ®Google Scholar
• Liu S, Li X, Li H, Liang Q, Chen J, Chen J. Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study. BMC Nephrol. 2015;16:200. doi:10.1186/s12882-015-0199-x
   PubMed Web of Science ®Google Scholar
• Wang W, Sheng L, Chen Y, et al. Total coumarin derivates from Hydrangea paniculata attenuate renal injuries in cationized-BSA induced membranous nephropathy by inhibiting complement activation and interleukin 10-mediated interstitial fibrosis. Phytomedicine. 2022;96:153886. doi:10.1016/j.phymed.2021.153886
   PubMed Web of Science ®Google Scholar
• Liu B, Lu R, Li H, et al. Zhen-Wu-Tang ameliorates membranous nephropathy rats through inhibiting NF-kappaB pathway and NLRP3 inflammasome. Phytomedicine. 2019;59:152913. doi:10.1016/j.phymed.2019.152913
   PubMed Web of Science ®Google Scholar
• Bonegio RG, Fuhro R, Wang Z, et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol. 2005;16(7):2063–2072. doi:10.1681/ASN.2004030180
   PubMed Web of Science ®Google Scholar
• Sun Z, Xu Q, Ma Y, Yang S, Shi J. Circ_0000524/miR-500a-5p/CXCL16 axis promotes podocyte apoptosis in membranous nephropathy. Eur J Clin Invest. 2021;51(3):e13414. doi:10.1111/eci.13414
   PubMed Web of Science ®Google Scholar
• Yang YQ, Liang J, Han XD, et al. Dual-function of triptriolide in podocytes injury: inhibiting of apoptosis and restoring of survival. Biomed Pharmacother. 2019;109:1932–1939. doi:10.1016/j.biopha.2018.11.031
   PubMed Web of Science ®Google Scholar
• Gao J, Liang Z, Zhao F, Liu X, Ma N. Triptolide inhibits oxidative stress and inflammation via the microRNA-155-5p/brain-derived neurotrophic factor to reduce podocyte injury in mice with diabetic nephropathy. Bioengineered. 2022;13(5):12275–12288. doi:10.1080/21655979.2022.2067293
   PubMed Web of Science ®Google Scholar
• Motavalli R, Etemadi J, Soltani-Zangbar MS, et al. Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy. Cytokine. 2021;141:155452. doi:10.1016/j.cyto.2021.155452
   PubMed Web of Science ®Google Scholar
• Gilbert A, Changjuan A, Guixue C, Jianhua L, Xiaosong Q. Urinary matrix metalloproteinase-9 and nephrin in idiopathic membranous nephropathy: a cross-sectional study. Dis Markers. 2021;2021:1620545. doi:10.1155/2021/1620545
   PubMedGoogle Scholar
• Qiu D, Kao PN. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D. 2003;4(1):1–18. doi:10.2165/00126839-200304010-00001
   PubMedGoogle Scholar
• Chiou TT, Chau YY, Chen JB, Hsu HH, Hung SP, Lee WC. Rapamycin attenuates PLA2R activation-mediated podocyte apoptosis via the PI3K/AKT/mTOR pathway. Biomed Pharmacother. 2021;144:112349. doi:10.1016/j.biopha.2021.112349
   PubMed Web of Science ®Google Scholar
• Meim X-D, Cao Y-F, Che -Y-Y, et al. Danshen: a phytochemical and pharmacological overview. Chin J Nat Med. 2019;17(1):59–80. doi:10.1016/s1875-5364(19)30010-x
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhang Y, Li L, Xie Z, Wen C, Huang L. Kunxian capsule for rheumatoid arthritis: inhibition of inflammatory network and reducing adverse reactions through drug matching. Front Pharmacol. 2020;11:485. doi:10.3389/fphar.2020.00485
   PubMed Web of Science ®Google Scholar
• Ma Z, Liu Y, Li C, Zhang Y, Lin N. Repurposing a clinically approved prescription Colquhounia root tablet to treat diabetic kidney disease via suppressing PI3K/AKT/NF-kB activation. Chin Med. 2022;17(1):2. doi:10.1186/s13020-021-00563-7
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jin D, Kang X, et al. Signaling pathways involved in diabetic renal fibrosis. Front Cell Dev Biol. 2021;9:696542. doi:10.3389/fcell.2021.696542
   PubMed Web of Science ®Google Scholar